U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24N2O4
Molecular Weight 368.4271
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARMOTEROL

SMILES

C[C@]([H])(Cc1ccc(cc1)OC)NC[C@@]([H])(c2ccc(c3c2ccc(n3)O)O)O

InChI

InChIKey=IHOXNOQMRZISPV-YJYMSZOUSA-N
InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H24N2O4
Molecular Weight 368.4271
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Carmoterol is a long-acting β2-adrenoceptor agonist with a rapid onset of action and potent bronchodilating activity. Carmoterol has a similar onset of action compared to salbutamol and formoterol, and a faster onset of action compared to salmeterol. Furthermore, the duration of tracheal smooth muscle relaxation is longer for carmoterol compared to both formoterol and salmeterol. In asthmatic patients, the PK of carmoterol is proportional to the dose, and nonlinear accumulation of the drug after repeated dosing treatments is negligible. In patients with persistent asthma carmoterol 2 µg administered once daily is as effective as formoterol 12 µg twice daily. Safety and tolerability results are similar between carmoterol and formoterol. There were no significant changes in ECG results, blood pressure or serum potassium or glucose levels

Originator

Curator's Comment:: Japanese journal of pharmacology (1991), 57, (2), 175-85.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.19 nM [Ki]
PubMed

PubMed

TitleDatePubMed
Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs.
2007
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: Kanniess F, Make BJ, Petruzzelli S. Acute effect of carmoterol, a long-acting β2-agonist, in patients with COPD [abstract] Proc Am Thorac Soc. 2008;5:A655. https://www.ncbi.nlm.nih.gov/pubmed/21232045
4 µg of 2 µg
Route of Administration: Respiratory
Substance Class Chemical
Created
by admin
on Sat Jun 26 11:11:40 UTC 2021
Edited
by admin
on Sat Jun 26 11:11:40 UTC 2021
Record UNII
9810NUL4D1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARMOTEROL
INN   MART.  
INN  
Official Name English
CARMOTEROL [MART.]
Common Name English
CARMOTEROL [INN]
Common Name English
TA-2005
Code English
CHF-4226
Code English
8-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)QUINOLIN-2(1H)-ONE
Systematic Name English
QUINOTEROL
Common Name English
Code System Code Type Description
EVMPD
SUB25400
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
CAS
147568-66-9
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
ChEMBL
CHEMBL1094785
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
NCI_THESAURUS
C171749
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
PUBCHEM
63952
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
INN
8404
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
FDA UNII
9810NUL4D1
Created by admin on Sat Jun 26 11:11:40 UTC 2021 , Edited by admin on Sat Jun 26 11:11:40 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SHORT-ACTING
Related Record Type Details
ACTIVE MOIETY